Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide consolidation versus observation after FC/FCR for chronic lymphocytic leukemia
ACTRN12610000060044Phase 3Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Lenalidomide consolidation with Observation (2 arms). Primary endpoint: Time to clinical disease progression or death. Started May 2011; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ACTRN12610000060044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000060044.